Abbott acquires Piramal's domestic formulations business for $3.7 billion
This article was originally published in Scrip
Executive Summary
Abbott has signed a definitive agreement to acquire Piramal Healthcare's domestic formulations business for an up-front payment of $2.12 billion and additional annual payments of $400 million for the next four years starting in 2011.